CN1187366A - Capsule for curing cancer - Google Patents
Capsule for curing cancer Download PDFInfo
- Publication number
- CN1187366A CN1187366A CN 97123267 CN97123267A CN1187366A CN 1187366 A CN1187366 A CN 1187366A CN 97123267 CN97123267 CN 97123267 CN 97123267 A CN97123267 A CN 97123267A CN 1187366 A CN1187366 A CN 1187366A
- Authority
- CN
- China
- Prior art keywords
- cancer
- capsule
- treatment
- clinical
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A capsule for curing cancer, especially the liver and lung cancers in metaphase and late phase is prepared from 9 Chinese-medicinal materials such as barbat skullcap, honeysuckle flower, scutellaria root, centipede, scorpion, etc., and features high curative effect, no toxic by-effect, and relaxing clinic symptom.
Description
The present patent application relates to a kind of cancer medicine of controlling, and particularly relating to a kind of is the treating the liver cancer and the pulmonary carcinoma capsule preparations of main formula components with Chinese herbal medicine.
Carninomatosis is physically and mentally healthy very harmful to people's, especially medium and advanced lung cancer patient, if without any treatment, its, major part had only about half a year or 1 year life cycle, and merged other internal organs transferrer, and life cycle is then shorter, and most of patients entered after late period, the severe pain that appearance is difficult to tolerate, even make the patient lose confidence to life, have a strong impact on its quality of life.At present, its curative effect of PTS SHENLING WAN is generally acknowledged.
The object of the present invention is to provide a kind of clinical every index to be not less than SHENLING WAN and the various symptoms of reduction of patient are better than SHENLING WAN and take cancer curing medicine without any side effects for a long time.
The present invention realizes with following technical scheme: the main component of cancer-treating capsule prescription is (by weight): Herba Scutellariae Barbatae 300g, Flos Lonicerae 150g, Radix Scutellariae 150g, Scolopendra 50g, Scorpio 50g, Squama Manis 60g, Herba Taraxaci 90g, Radix Isatidis 90g, Nidus Vespae 60g proportioning are made 1000 capsules preparations, and every contains crude drug 2g.
Anticancer mechanism: theory of Chinese medical science thinks that cancer belongs to the disease product category, the generation that disease is long-pending, how because of the pent-up of feelings will, cold-evil enemy intrusion or invasion, body void causes that positive QI-insufficiency, internal organs are become estranged after being ill, blood vessels in evil malicious internal resistance, numbness, with the passing of time in fire-transformation, the pyretic toxicity, disease is obstructed, stops, is with the passing of time become to QI-blood circulation in internal organs, blood stasis long-pending.It then is a lump in the right hypochondrium the lung person.The tortoise beetle cancer-treating capsule is made up of Chinese medicines such as Herba Scutellariae Barbatae, Flos Lonicerae, Radix Scutellariae, Squama Manis, Scorpios.Herba Scutellariae Barbatae has heat-clearing and toxic substances removing in the side, the dissipating blood stasis for subsidence of swelling effect, but and cough-relieving, eliminate the phlegm, relieving asthma.But heat-clearing and toxic substances removing such as Flos Lonicerae, Radix Scutellariae is gone into lung meridian Squama Manis, Scorpio, Scolopendra partially and is gone into Liver Channel partially dredge the meridian passage, hard masses softening and resolving, pain relieving are arranged, and can reach the disease place by the meridian dredging, with the promoting the circulation of blood eliminating stagnation.The tortoise beetle cancer-treating capsule has the effect of heat-clearing and toxic substances removing, blood circulation promoting and dispersing pathogen accumulation in a word, and merit is long-pending and just do not hinder, and eliminating mass is double to be set upright, thereby is excellent to treatment hepatocarcinoma, pulmonary carcinoma especially to the treatment of carcinoma.Modern medicine study, Herba Scutellariae Barbatae are in zoopery, and to S180, Chinese mugwort stilbene ehrlich ascites carcinoma, cerebroma 22 have inhibitory action, and golden Fructus Vitis viniferae, bacillus pyocyaneus, escherichia coli, dysentery bacterium etc. are had inhibitory action.Flos Lonicerae also is a broad spectrum antibiotic.Squama Manis has function of increasing leukocyte, can increase body's immunity.So the tortoise beetle cancer-treating capsule is effective to treatment for cancer.
The beneficial effect that the present invention had: owing in the side Herba Scutellariae Barbatae etc. is arranged, energy heat-clearing and toxic substances removing, dissipating blood stasis for subsidence of swelling; Heat and toxic materials clearing away medicine such as Flos Lonicerae, Radix Scutellariae are arranged, can strengthen the removing toxic substances and promoting subsidence of swelling effect of Herba Scutellariae Barbatae; Medicines such as Squama Manis, Scorpio are arranged, energy dredge the meridian passage, hard masses softening and resolving.All medicines rationally mutually 5 in the prescription, can hard masses softening and resolving, again can dredge the meridian passage, and then cancer is cured or is controlled its development.Mainly observe the tortoise beetle cancer-treating capsule to carcinoma patient's curative effect, malicious pair or untoward reaction from following to mice and rat animal toxicity test and long term toxicity test and provincial hospital, three hospital clinicals of the province tumour hospital and the province academy of traditional Chinese medicine, and with generally acknowledge that effective PTS SHENLING WAN compares checking.One, three hospital clinicals research: 1, research purpose: mainly observe the clinical efficacy of tortoise beetle cancer-treating capsule to the carcinoma patient, malicious pair or untoward reaction, and with generally acknowledge that effective PTS " SHENLING WAN " compares checking.2, the sick kind selected: select the clinical primary lung cancer of seeing more.3, administrated method: tortoise beetle cancer-treating capsule: oral 4 times of every day, each 4 (3 gram), 2 months is a course of treatment.SHENLING WAN: oral 4 times of every day, each 3 grams, 2 months is a course of treatment.4, test routine number: the total routine number of test group must not be less than 300 examples, and matched group is no less than 100 examples.Three hospital's mean allocation example numbers.5, grouping: adopt randomized blocks.6, diagnostic criteria: to the diagnosis of primary lung cancer, removing has cough, spitting of blood, chest pain, fever, hoarseness, outside the clinical manifestations such as Hornet syndrome, superior vena cava syndrome, pernicious hydrothorax, supraclavicular lymph nodes transfer, clear and definite objective diagnosis index must be arranged.The positive finding that X line plain film, tomography X-ray sheet, CT, MRI, branchofiberoscope, expectorant exfoliative cyte, hydrothorax cell, metastatic lymph node biopsy etc. promptly will be arranged, or specimens from pri is through the pathology prover.7, standard by stages: the TNM stadium classification method of by stages announcing of pulmonary carcinoma by International Union of Counter Cancer.8, state of an illness grade scale: press the standards of grading that Karnofsky formulates, or press the grade scale that The World Health Organization (WHO) formulates.9, include the case standard in: 9.1 turn out to be the patient of pulmonary carcinoma through pathology or cytology.9.2 inoperable II～IV phase patients with lung cancer comprises the patient that operation fails to excise cancer.9.3 without other treatment, or put, end of chemotherapy person more than 2 months, or recurrence after operation person.9.4 press Karnofsky scoring more than 40 minutes (or WHO classification 3 grades), the estimation person more than 3 months of surviving.9.5 the age is more than 18 years old, male or female.10, get rid of the case standard, comprise rejecting standard or inadaptation; 10.1 have the inclination, serious disease persons such as liver, kidney the psychotic.10.2 put, chemotherapy, or put, 2 months persons of end of chemotherapy less than.10.3 do not meet the standard of including in, not medication in accordance with regulations, data not all or none method is judged curative effect person.11, observation content: 11.1 safeties observation: comprise general health check-up project, blood, urine, just routine test, the heart, liver, kidney function test.11.2 health giving quality observation: following three aspects of main observation: 11.2.1 cancer change in volume: according to regularly making the result that X line, CT etc. detect.11.2.2 quality of life changes: comprise symptom, sign and tcm syndrome, muscle power etc.11.2.3 life cycle, length because the time limit of II phase clinical research is shorter, was observed so only make recent existence situation.11.3 observation time: stipulate 4 times, promptly the treatment during, the treatment back 3 months, half a year, 1 year.Check every observation contrast content when the time comes.12, efficacy determination: mainly the result according to safety observation and curative effect observation judges.The cancer change in volume is divided four kinds of situations: complete obiteration (CR); Part is alleviated (PR, cancer dwindle 〉=50%); Stable (NR, cancer dwindle＜50% or enlarge＜25%); And progress (the PD cancer enlarges＞50%).Quality of life changes according to clinical symptoms sign and Karnofsky scoring or WHO classification results.Life span refers to that treatment begins to death, or the not inferior time of following up a case by regular visits to.13, clinical data: 13.1 physical data: since nineteen ninety-five, three hospitals accept primary lung cancer 488 examples that meet the standard of including in altogether for medical treatment, complete data person 434 examples wherein, i.e. provincial hospital's 148 examples, province tumour hospital 141 examples, the province academy of traditional Chinese medicine 145 examples.Test group 314 examples, matched group 120 examples.The male accounts for 70.3%, and the women accounts for 29.7%.Accounted in＜39 years old and accounted for 44% in 12.6%, 40～59 years old, accounted for 43.4% in＞50 years old.13.2 safety is judged: during treating, occur the mild nausea after 1 routine medication is organized in treatment, all do not find any untoward reaction, also do not find the infringement to the heart, liver, kidney for all the other two groups.13.3 efficacy determination: 13.3.1 treats forward and backward quality of life and changes: statistics begins quality of life situation of change to the half a year from treatment.See Table one.
The forward and backward two groups of quality of lifes variation of table one treatment relatively
| Group | The example number | Rise | Stable | Descend | Raising rate % |
| The test group matched group | ????314 ????120 | ????118 ????37 | ????171 ????77 | ????25 ????6 | ??37.5％ ??30.8％ |
X
2=3.498 P＞0.005 is not remarkable.From statistical result, two groups of quality of lifes are improved.There is not significant difference between two groups.13.3.2 cancer change in volume situation: the observation treatment begins to see Table two to the situation of change between the tailend course of treatment.
Two groups of cancer situation of change contrasts before and after table two treatment
| Group | The example number | Complete obiteration (CR) | Dwindle 〉=50% (PR) | Dwindle＜50% or enlarge＜25% (NR) | Enlarge 25% (PD) | Effective percentage % (CR+PR+NR) |
| The test group matched group | 314 120 | ?1(0.6％) ?0(0％) | 79(25％) 21(17.5) | 129(4％) 57％(47.5) | 105(33.4％) 42(35％) | ????66.6％ ????65％ |
X
2=2.551 P＞0.005 is not remarkable.From the visible test group effective percentage of table two is 66.6%, and the matched group effective percentage is 65%.Learn by statistics and handle, two groups are not had significant difference.13.3.3 symptom variation situation before and after the treatment: observation sees Table three till beginning to finish to the course of treatment from treatment.
Symptom variation situation before and after table three treatment
More than every two groups of contrasts, through X
2Check all has notable difference, and test group is better than matched group.13.3.4 survival rate: shorter because of observation time, can only add up 1 year survival rate at present, see Table four.
| Symptom | Group | The example number | Alleviate fully | Part is alleviated | Stable | Progress | ????X????P |
| Respiratory symptom | The test group matched group | ??408 ??170 | ????0 ????0 | ??164 ??54 | ???153 ????66 | ??91 ??50 | ????X＝536.96 ????P＜0.005 |
| Pain | The test group matched group | ??213 ??93 | ????41 ????7 | ??93 ??29 | ????43 ????47 | ??36 ??10 | ????X＝335.69 ????P＜0.005 |
| Heating | The test group matched group | ??166 ??58 | ????49 ????12 | ??54 ??20 | ????47 ????17 | ??16 ??9 | ????X＝226.69 ????P＜0.005 |
| It is weak to become thin | The test group matched group | ??277 ??99 | ????1 ????0 | ??170 ??59 | ????67 ????25 | ??39 ??15 | ????X＝378.38 ????P＜0.005 |
| Anorexia | The test group matched group | ??178 ??69 | ????58 ????13 | ??74 ??27 | ????34 ????23 | ??12 ??6 | ????X＝254.66 ????P＜0.005 |
Back 1 year existence situation of table four treatment
See the characteristics of tortoise beetle cancer-treating capsule from two groups of contrasts: from every result of clinical research, unique between two groups there were significant differences that to be the tortoise beetle cancer-treating capsule be better than SHENLING WAN (every P value is all less than 0.005) to the various symptoms of reduction of patient.Concerning the patient of middle and terminal cancer, this point is extremely important, pain problem for example, and most of patients entered after late period, the severe pain that is difficult to tolerate occurred, and this makes the patient lose confidence to life, has a strong impact on its quality of life.The tortoise beetle cancer-treating capsule can reach 62.9% (seeing Table three pain items 134/213) to the remission rate of patient's pain and obviously be better than SHENLING WAN (36/93=38.7%).This report only limits to the short term effect observation to patients with lung cancer treatment, its late result and long-term survival rate follow up a case by regular visits to observation, and, remain further to be finished from now on to other carcinoma patient's curative effect.Toxicity test and long-term toxicity test for animals: one, tortoise beetle cancer-treating capsule acute toxicity test: 1, experiment material: (1) supplies the reagent thing: the tortoise beetle cancer-treating capsule is provided by the safe and comfortable Chinese and western medicine in Harbin City institute of oncology, lot number: 940905, every capsules powder charge powder 0.5g.(2) usage and consumption: oral 3 times of every day of adult, each 8, warm water delivery service.(3) method for preparation of drug: the powder 40g that gets it filled puts in the mortar, and adding distil water has reached Cmax to the Aikangning medicine for treating cancer medicated powder suspension that 100ml makes 40% concentration while grinding.(4) experimental animal: Kunming kind white mice, body weight 18～22g, male and female half and half are provided by laboratory animal room of Harbin railway central hospital.Maximum tolerance determination: its objective is by the mice maximum tolerance determination, observe the dosis tolerata of tortoise beetle cancer-treating capsule to animal, measure the multiple that it can reach the human clinical dosage, thereby this drug safety is made an appraisal, be pharmacodynamics for clinical application provides with reference to reaching, long poison research provides foundation.Get 20 of healthy mices, male and female half and half, the normal raising after 2 days, every mice gavages the Aikangning medicine for treating cancer capsule medicated powder suspension of 40% concentration by 0.4ml/10g, is equivalent to the crude drug of 16g/kg dosage, to reach Cmax, gavage continuously in one day three times, each 6 hours at interval, observe mice active situation and dead number of elements in seven days continuously, calculate the multiple that is equivalent to people's clinical application by above-mentioned dose, its computing formula is as follows:
| Group | The example number | Lose and visit | Dead | Case fatality rate | ??X????P |
| The test group matched group | ??314 ??120 | ????34 ????13 | ????56 ????27 | ?28.7％(90/314) ?33.3％(40/120) | X＝12.84 P＞0.005 |
The result sees table 1 for details.
Table 1 tortoise beetle cancer-treating capsule is to mice maximum tolerance determination method
After mice gavages administration by above-mentioned dosage.All do not have dead mouse in 7 days, the mice activity freely, diet is normal, hair color gloss, no loose stool etc., the maximum tolerated dose of this medicine mice is 48g/kg as calculated, 200 times of quite dried clinical adult's consumption think that this medicine clinical oral administration medication is safer.Two, long-term toxicity test for animals: get 80 of rats, be divided into 4 groups at random, make blank group and basic, normal, high dosed administration group respectively.High dose group is 30 times of Coming-of-Age Day therapeutic dose by the 9.6g/kg administration.Test period is 90 days, administration every day 1 time, continuous 90 days.Observe testing result: the general state of rat, growth promoter, body weight, diet, hematological examination, liver, kidney function test, anatomy and pathology histological examination etc., basic, normal, high three dosage groups and blank group compare, and all no significant difference is not seen the toxicity pathological change yet.Clinical the taking of the same proof of this test tortoise beetle cancer-treating capsule is safe.Therefore, no matter from clinical research result and toxicity test and long-term toxicity test for animals, show that all the tortoise beetle cancer-treating capsule is without any side effects, this test group major part is the middle and advanced stage patient, it is nearly 1/3 to merge other internal organs transferrers, and majority all once tossed about in bed can't treat in various big hospital.After this part patient adopted the treatment of tortoise beetle cancer-treating capsule, it was 71.3% that the objective indicator effective percentage reaches 66.6%, 1 year survival rate.Illustrate that this medicine has certain curative effect to the cancer patient.It not only can alleviate clinical symptoms, improves the quality of living, and also can prolong life, improves survival rate, is the medicine that is worth medium and advanced lung cancer patient recommendation.
| Number of animals (only) | Drug level (%) | Administration volume (ml/kg) | Administration number of times (next day) | Dosage (g/kg) | Observing time (my god) | Death toll (only) | Clinical application multiple (doubly) |
| 20 | ?40 | ????40 | ????3 | ????48 | ???7 | ????0 | ??200 |
Description of drawings:
Accompanying drawing is a tortoise beetle cancer-treating capsule preparation technology flow chart.
Describe the present invention in detail below in conjunction with embodiment and accompanying drawing.The Main Ingredients and Appearance of tortoise beetle cancer-treating capsule prescription is (by weight): Herba Scutellariae Barbatae 300g, Flos Lonicerae 150g, Radix Scutellariae 150g, Scolopendra 50g, Scorpio 50g, Squama Manis 60g, Herba Taraxaci 90g, Radix Isatidis 90g, Nidus Vespae 60g make 1000, and every contains crude drug 2g.Accompanying drawing has provided the preparation technology of tortoise beetle cancer-treating capsule: above nine flavors, and wherein Radix Scutellariae, Scolopendra, Scorpio are ground into fine powder; All the other Six-elements decoct with water three times, and amount of water is respectively 12 times, 10 times, 8 times, 2 hours for the first time, second and third time each 1 hour, merge medicinal liquid, filter, filtrate is condensed into the extractum that relative density is 1.16～1.20 (80 ℃ of surveys), spray drying, in the spraying liquid process with fine powder mixings such as above-mentioned Radix Scutellariae, dry powder alcohol granulation, drying, sieve, promptly encapsulated.This preparation is made up of nine flavor Chinese medicines, is consulting on the basis of relevant document, according to the physicochemical property and the clinical pharmacology practice of each flavor medicine, in conjunction with the traditional medication custom and the characteristics of capsule, production technology is studied, to guarantee drug quality.1, Radix Scutellariae, Scorpio, Scolopendra are used as medicine with former powder.The Radix Scutellariae agents area is a root, contains baicalin, baicaligenin, wogonin, wogonoside, also contains aminoacid, volatile oil and polysaccharide.Clinical pharmacology shows that baicalin and baicaligenin have the effect and the sedation of antiinflammatory antiallergic action; Radix Scutellariae decocting liquid has wider antimicrobial spectrum, dysentery bacterium, diphtheria corynebacterium, bacillus pyocyaneus, staphylococcus, streptococcus, Diplococcus pneumoniae and meningococcus all there are inhibitory action, also have effects such as antiviral, analgesic, blood pressure lowering, diuresis, function of gallbladder promoting, spasmolytic simultaneously.Radix Scutellariae ether extract tool antitumaous effect, the in vitro tests of Radix Scutellariae decoct has been duplicated inhibitory action to hepatitis B virus DNA.Comprehensive its pharmacological action for giving full play to drug effect, is advisable with starch.It is the Neurotoxic protein of a kind of similar snake venom that Scorpio contains scorpion venom; also contain trimethylamine, betanin, taurine, cholesterol and stearic acid ammonium salt etc.; the pharmacological evaluation proof has convulsion, hypotensive effect; tumor there are prevention and therapeutical effect; can fry in shallow oil soup or go into ball, diffusing; clinical many and the application of Scolopendra compatibility are in order to treat insane, arthralgia pain, tuberculous lymphadenitis etc.Scolopendra contains two kinds of toxic components like Venenum apis, be histamine sample material and hemolytic albumen, still contain fatty oil, cholesterol, formic acid and several amino acids etc., have antitumor, antibiotic, spasmolytic and promote the effect of immunologic function, clinical report dries with Scolopendra and grinds into powder, 2 to 3 treatments every day cancer, have at most and use every day to 6, also do not see toxic reaction, according to pharmacological testing and traditional clinical application experience, Scorpio, Scolopendra should be with starch.2, the selection of all the other flavour of a drug decocting extraction process conditions: Herba Scutellariae Barbatae contains alkaloid, flavonoid glycoside, phenols and steroidal, that pharmacological testing proof has is antibacterial, spasmolytic is ended expectorant, pressed down tumor and immunoregulation effect, and its decocting liquid of clinical report can be used for treating cancer, lung abscess etc.Flos Lonicerae contains chlorogenic acid, isochlorogenic acid, luteolin and inositol etc., has antibiotic, resisting pathogenic microbes and strengthens the effect of body defensive enginery, and is clinical many to be decocted in water for oral dose, with doing treatment pneumonia, pulmonary tuberculosis complicated with respiratory tract infection and surgery purulent disease.Squama Manis contains two aliphatic amides, volatile oil, water-soluble alkaloid and aminoacid, trace element of stearic acid, cholesterol, carbon number 26 and 29 etc., and its decocting liquid has the effect of antiinflammatory, blood viscosity lowering.Herba Taraxaci contains taraxasterol, choline, inulin, pectin etc., has the effect of antibiotic, antitumor, function of gallbladder promoting, lactogenesis.That Radix Isatidis contains is indigo, indirubin, cupreol and aminoacid, saccharide etc., has the immunologic function of raising, antitumor action etc., and its decocting liquid can be used for treating hepatitis, liver cirrhosis and influenza, parotitis etc.According to the physicochemical property of above all medicine ingredients, can in water, dissolve mostly, so, be the fried index of effective ingredient, screen optimum extraction condition with chlorogenic acid content in the Flos Lonicerae with its effective ingredient of water boiling and extraction.The experiment proved that extraction time has the greatest impact to the result, the decocting time influence is minimum.Decocting 3 times, each 2 hours, amount of water was that chlorogenic acid content is the highest under 12 times the condition.Consider that all grass herb is more in the said preparation, water absorption is bigger for the first time, so amount of water is 12 times for the first time, is decremented to 10 times, 8 times successively.From the fried amount of chlorogenic acid, extract each 1 hour 3 times, with extraction 3 times, each 2 hours relatively, and difference is also not very big, in energy savings, shortening time and under the prerequisite that do not affect the treatment, with this technology fixed with: extract three times, 2 hours for the first time, second and third time each 1 hour, amount of water are 12 times for the first time, 10 times for the second time, 8 times for the third time, the herbal decoction recovery rate is about 21.6% in dried cream.
Character: this product content is pale brown color, gas raw meat, bitter in the mouth, puckery.
Function with cure mainly: heat-clearing and toxic substances removing, movable blood soft hard, mass dissipating and swelling eliminating.Be used for the multiple cancer that the pyretic toxicity blood stasis stagnates and forms, be mainly used in pulmonary carcinoma, hepatocarcinoma.
Usage and consumption: oral, four times on the one, one time four or follow the doctor's advice.
Contraindication: be not taken by pregnant women;
Attention: avoid pungent food:
Specification: every dress 0.35g;
Storage: sealing;
Useful life: tentative 2 years.
Claims (1)
1, a kind of cancer-treating capsule is characterized in that the main component of filling a prescription is (by weight): Herba Scutellariae Barbatae 300g, Flos Lonicerae 150g, Radix Scutellariae 150g, Scolopendra 50g, Scorpio 50g, Squama Manis 60g, Herba Taraxaci 90g, Radix Isatidis 90g, Nidus Vespae 60g proportioning are made every and are contained crude drug 2g 1000 capsules preparations altogether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97123267 CN1187366A (en) | 1997-12-18 | 1997-12-18 | Capsule for curing cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97123267 CN1187366A (en) | 1997-12-18 | 1997-12-18 | Capsule for curing cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1187366A true CN1187366A (en) | 1998-07-15 |
Family
ID=5177045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97123267 Pending CN1187366A (en) | 1997-12-18 | 1997-12-18 | Capsule for curing cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1187366A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
-
1997
- 1997-12-18 CN CN 97123267 patent/CN1187366A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105943615A (en) | Application of whole hemp extract in preparation of pancreatic cancer treating drug | |
| CN102961573A (en) | Medicine for treating pulmonary interstitial fibrosis and preparation method thereof | |
| CN113368207B (en) | Traditional Chinese medicine compound for treating convalescent stage of Xinguan pneumonia and application of traditional Chinese medicine compound for treating respiratory tract infection | |
| CN102579803B (en) | Medicine for treating post-chemotherapy leucopenia and preparation method thereof | |
| CN105878938A (en) | Pharmaceutical preparation for treating lung cancer and application thereof | |
| CN113827657A (en) | Traditional Chinese medicine composition preparation for treating epidemic cold (qi-yin deficiency syndrome) and application | |
| CN103142842A (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN102188689B (en) | Compound combination medicament for treating COPD, preparation method and application thereof | |
| CN102698207A (en) | Traditional Chinese medicine composition for treating hepatopathy and preparation method thereof | |
| CN101810826B (en) | Chinese medicament for treating liver cancer | |
| CN117599125A (en) | A Chinese medicinal composition for supplementing calcium and strengthening bones for treating osteoporosis, and its preparation method and application | |
| CN106038637A (en) | Pharmaceutical composition for treating breast cancer | |
| CN112336802B (en) | Traditional Chinese medicine composition for improving glycolipidosis metabolism of diabetes and application thereof | |
| CN103110100A (en) | Korean medical healthcare food composition as well as preparation method and application thereof | |
| CN101342313B (en) | Health care granular formulation, preparation and application thereof | |
| CN1187366A (en) | Capsule for curing cancer | |
| CN1310662C (en) | Chinese medicine for coronary heart disease | |
| CN113599447A (en) | Traditional Chinese medicine composition for improving phlegm-dampness constitution and preparation method and application thereof | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN103536879A (en) | Pharmaceutical composition for treating diabetes mellitus and preparation method thereof | |
| CN115105576B (en) | Traditional Chinese medicine composition for treating ovarian cancer, traditional Chinese medicine preparation and application thereof | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN116211974B (en) | Traditional Chinese medicine composition for improving microcirculation of human body | |
| CN103417906A (en) | Applications of compound mylabris traditional Chinese medicine composition and preparations thereof in preparing drugs for curing depression | |
| CN112043757B (en) | Health-preserving coffee and traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1018216 Country of ref document: HK |